O
IMGN

OrbiMed’s Immunogen Inc IMGN Stock Holding History

OrbiMed’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,868,786
Closed -$28.7M – 167
2021
Q4 		$28.7M Sell
3,868,786
-11,029,128
-74% -$68.5M 0.37% 67
2021
Q3 		$84.5M Buy
14,897,914
+1,961,292
+15% +$11.3M 0.93% 32
2021
Q2 		$85.3M Buy
12,936,622
+3,804,800
+42% +$26.5M 0.86% 38
2021
Q1 		$74M Buy
9,131,822
+6,577,922
+258% +$53.7M 0.69% 44
2020
Q4 		$16.5M Buy
+2,553,900
New +$14.9M 0.14% 110
2020
Q1 		– Sell
-286,800
Closed -$1.46M – 164
2019
Q4 		$1.46M Buy
+286,800
New +$973K 0.02% 123
2018
Q4 		– Sell
-1,469,189
Closed -$13.9M – 156
2018
Q3 		$13.9M Sell
1,469,189
-1,435,081
-49% -$13.8M 0.17% 100
2018
Q2 		$28.3M Buy
2,904,270
+1,400,000
+93% +$14.8M 0.34% 71
2018
Q1 		$15.8M Sell
1,504,270
-1,329,856
-47% -$13.1M 0.2% 89
2017
Q4 		$18.2M Sell
2,834,126
-2,616,455
-48% -$16.1M 0.23% 81
2017
Q3 		$41.7M Buy
5,450,581
+1,512,309
+38% +$10M 0.4% 68
2017
Q2 		$28M Sell
3,938,272
-2,157,375
-35% -$9.87M 0.29% 73
2017
Q1 		$23.6M Hold
6,095,647
– – 0.27% 74
2016
Q4 		$12.4M Hold
6,095,647
– – 0.16% 81
2016
Q3 		$16.3M Hold
6,095,647
– – 0.19% 81
2016
Q2 		$18.8M Hold
6,095,647
– – 0.2% 74
2016
Q1 		$51.9M Hold
6,095,647
– – 0.55% 45
2015
Q4 		$82.7M Buy
6,095,647
+2,501,647
+70% +$30.8M 0.75% 41
2015
Q3 		$34.5M Buy
3,594,000
+2,564,000
+249% +$37.5M 0.35% 56
2015
Q2 		$14.8M Buy
+1,030,000
New +$11.3M 0.12% 92

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's IMGN Position: Q1 2022 in Review

OrbiMed sold out of Immunogen Inc (IMGN) in Q1 2022, closing a stake of 3,868,786 shares — an estimated $28.7M sold.

OrbiMed first reported a position in IMGN in Q2 2015 and held it in 20 quarters. The position peaked at $85.3M in Q2 2021. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2022.

  • OrbiMed reported no remaining Immunogen Inc position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 3,868,786 Immunogen Inc shares in Q1 2022, an estimated $28.7M.
  • OrbiMed first reported a position in Immunogen Inc in Q2 2015 and held it in 20 quarters.
  • OrbiMed's Immunogen Inc position peaked at $85.3M in Q2 2021.
  • 217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.